Imatinib mesylate STI571 therapy for five patients with advanced gastrointestinal stromal tumors.
- Author:
Kun-tang SHEN
1
;
Ying-yong HOU
;
Xin-yu QIN
;
Lu-jun SONG
;
Akesu SUJIE
Author Information
- Publication Type:Case Reports
- MeSH: Adult; Aged, 80 and over; Benzamides; Female; Gastrointestinal Stromal Tumors; drug therapy; pathology; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasm Staging; Piperazines; therapeutic use; Proto-Oncogene Proteins c-kit; metabolism; Pyrimidines; therapeutic use; Retrospective Studies
- From: Chinese Journal of Gastrointestinal Surgery 2005;8(2):129-131
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo explore the therapeutic effect of STI571(imatinib mesylate) on advanced gastrointestinal stromal tumors (GISTs).
METHODSClinical data of 5 cases with advanced GISTs were analyzed retrospectively.
RESULTSThe expression of c- kit (CD117) was detected by immunohistochemical method in five patients with advanced GISTs . All patients failed to systematic chemotherapy or radiofrequency and operation because of extensive and multiple metastases (4 cases underwent 1 to 3 times of exploratory surgery). Tumor size was markedly decreased one to six months after STI571 given without serious drug- related side effects.
CONCLUSIONSSTI571 is an effective chemotherapy for advanced unresectable or metastatic GISTs. Inhibitor of the Kit signal- transduction pathway is a promising regimen that is different from conventional chemotherapy for advanced GISTs.
